HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activin-A, transforming growth factor-beta, and myostatin signaling pathway in experimental dilated cardiomyopathy.

AbstractBACKGROUND:
The pathogenic mechanisms of dilated cardiomyopathy are still uncertain. A number of cytokines and growth factors participate in the remodeling process of the disease.
METHODS:
We investigated the cardiac myostatin, transforming growth factor (TGF)beta, and activin-A/Smad growth inhibitory signaling pathway in experimental dilated cardiomyopathy. Transvenous endomyocardial biopsies of the interventricular septum were taken weekly in 15 beagle dogs during the development of heart failure (HF) induced by rapid pacing over a period of 7 weeks. Genes involved in the myostatin-TGFbeta-activin-A/Smad signaling pathway and the cardiac hypertrophic process were quantified by real-time quantitative polymerase chain reaction. Left ventricular volume, function, and mass were evaluated by echocardiography.
RESULTS:
Overpacing was associated with increased left ventricular volumes and decreased ejection fraction, whereas the left ventricular mass remained unchanged. TGFbeta was increased in moderate HF. Activin-A mRNA expression was 4-fold higher in overt congestive HF than at baseline. A 2-fold decrease of activin type II receptors and activin receptor interacting protein 2 gene expressions were observed, as well as a transient decrease of follistatin. Activin type I receptors, activin receptor interacting protein 1, follistatin-related gene, and myostatin remained unchanged. The inhibitory Smad 7, a negative feedback loop regulator of the Smad pathway, was overexpressed in severe HF. Gene expression of the cyclin-dependent kinase inhibitor p21, a direct target gene of the Smad pathway, was 8-fold up-regulated in HF, whereas cyclin D1 was down-regulated.
CONCLUSION:
We conclude that tachycardia-induced dilated cardiomyopathy is characterized by gene overexpression of the TGFbeta-activin-A/Smad signaling pathway and their target gene p21 and by the absence of ventricular hypertrophy.
AuthorsMaryam Mahmoudabady, Myrielle Mathieu, Laurence Dewachter, Ielham Hadad, Lynn Ray, Pascale Jespers, Serge Brimioulle, Robert Naeije, Kathleen McEntee
JournalJournal of cardiac failure (J Card Fail) Vol. 14 Issue 8 Pg. 703-9 (Oct 2008) ISSN: 1532-8414 [Electronic] United States
PMID18926443 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cytokines
  • Intercellular Signaling Peptides and Proteins
  • Myostatin
  • activin A
  • Activins
  • Cyclin D1
Topics
  • Activins (metabolism)
  • Animals
  • Cardiomyopathy, Dilated (diagnostic imaging, genetics, metabolism)
  • Cyclin D1 (metabolism)
  • Cyclin-Dependent Kinase Inhibitor p21 (metabolism)
  • Cytokines (metabolism)
  • Disease Progression
  • Dogs
  • Gene Expression
  • Intercellular Signaling Peptides and Proteins (metabolism)
  • Models, Animal
  • Myostatin (metabolism)
  • Signal Transduction
  • Ultrasonography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: